198 related articles for article (PubMed ID: 35221496)
1. Survey of tumorigenic sensitivity in 6-month rasH2-Tg mice studies compared with 2-year rodent assays.
Hisada S; Tsubota K; Inoue K; Yamada H; Ikeda T; Sistare FD
J Toxicol Pathol; 2022 Jan; 35(1):53-73. PubMed ID: 35221496
[TBL] [Abstract][Full Text] [Related]
2. The Tg rasH2 mouse in cancer hazard identification.
Morton D; Alden CL; Roth AJ; Usui T
Toxicol Pathol; 2002; 30(1):139-46. PubMed ID: 11890467
[TBL] [Abstract][Full Text] [Related]
3. Rapid induction of more malignant tumors by various genotoxic carcinogens in transgenic mice harboring a human prototype c-Ha-ras gene than in control non-transgenic mice.
Yamamoto S; Mitsumori K; Kodama Y; Matsunuma N; Manabe S; Okamiya H; Suzuki H; Fukuda T; Sakamaki Y; Sunaga M; Nomura G; Hioki K; Wakana S; Nomura T; Hayashi Y
Carcinogenesis; 1996 Nov; 17(11):2455-61. PubMed ID: 8968063
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the Carcinogenic Potential of Enarodustat (JTZ-951), a Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor, in 26-Week Tg.rasH2 Mouse Study and 2-Year Sprague-Dawley Rat Study.
Kemmochi Y; Toyoda K; Ishida T; Yasui Y; Shoda T
Int J Toxicol; 2023 Dec; 42(6):489-503. PubMed ID: 37480334
[TBL] [Abstract][Full Text] [Related]
5. Twenty-six-week carcinogenicity study of sulfamethoxazole in CB6F1-Tg-rasH2 mice.
Torii M; Itoh F; Yabuuchi K; Ohno K; Kominami G; Hirano K; Tasaki T; Nara H
J Toxicol Sci; 2001 May; 26(2):61-73. PubMed ID: 11429969
[TBL] [Abstract][Full Text] [Related]
6. Tg.rasH2 Mice and not CByB6F1 Mice Should Be Used for 28-Day Dose Range Finding Studies Prior to 26-Week Tg.rasH2 Carcinogenicity Studies.
Paranjpe MG; Belich J; Vidmar TJ; Elbekai RH; McKeon M; Brown C
Int J Toxicol; 2017; 36(4):287-292. PubMed ID: 28553733
[TBL] [Abstract][Full Text] [Related]
7. Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing.
Yamamoto S; Urano K; Koizumi H; Wakana S; Hioki K; Mitsumori K; Kurokawa Y; Hayashi Y; Nomura T
Environ Health Perspect; 1998 Feb; 106 Suppl 1(Suppl 1):57-69. PubMed ID: 9539005
[TBL] [Abstract][Full Text] [Related]
8. Twenty-six-Week carcinogenicity study of chloroform in CB6F1 rasH2-transgenic mice.
Sehata S; Maejima T; Watanabe M; Ogata S; Makino T; Tanaka K; Manabe S; Takaoka M
Toxicol Pathol; 2002; 30(3):328-38. PubMed ID: 12051550
[TBL] [Abstract][Full Text] [Related]
9. High Background Incidence of Spontaneous Subcapsular Adrenal Gland Hyperplasia of Tg.rasH2 Mice Used in 26-week Carcinogenicity Studies.
Boyle MH; Paranjpe MG; Creasy DM
Toxicol Pathol; 2018 Jun; 46(4):444-448. PubMed ID: 29695215
[TBL] [Abstract][Full Text] [Related]
10. Regulatory Forum Commentary* Counterpoint: Dose Selection for Tg.rasH2 Mouse Carcinogenicity Studies.
Darbes J; Sistare FD; DeGeorge JJ
Toxicol Pathol; 2015 Jul; 43(5):621-7. PubMed ID: 26047967
[TBL] [Abstract][Full Text] [Related]
11. Interlaboratory comparison of short-term carcinogenicity studies using CB6F1-rasH2 transgenic mice.
Takaoka M; Sehata S; Maejima T; Imai T; Torii M; Satoh H; Toyosawa K; Tanakamaru ZY; Adachi T; Hisada S; Ueda M; Ogasawara H; Matsumoto M; Kobayashi K; Mutai M; Usui T
Toxicol Pathol; 2003; 31(2):191-9. PubMed ID: 12696579
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the Class Effects of Antisense Oligonucleotides in CByB6F1-Tg(HRAS)2Jic and CD-1 Mice.
Kim TW; Papagiannis CN; Zwick LS; Engelhardt JA; Hoffmaster CM; Post NM; Matson JE; Hsiao JA; Burel SA; Henry SP
Toxicol Pathol; 2019 Jan; 47(1):82-92. PubMed ID: 30585133
[TBL] [Abstract][Full Text] [Related]
13. The 26-week Tg.rasH2 mice carcinogenicity studies: microscopic examination of only select tissues in low- and mid-dose groups.
Paranjpe MG; Denton MD; Elbekai RH
Toxicol Pathol; 2014 Oct; 42(7):1153-7. PubMed ID: 23960167
[TBL] [Abstract][Full Text] [Related]
14. Pathological features of spontaneous and induced tumors in transgenic mice carrying a human prototype c-Ha-ras gene used for six-month carcinogenicity studies.
Mitsumori K; Koizumi H; Nomura T; Yamamoto S
Toxicol Pathol; 1998; 26(4):520-31. PubMed ID: 9715511
[TBL] [Abstract][Full Text] [Related]
15. Examination of percutaneous application in a 26-week carcinogenicity test in CB6F1-TG rasH2 mice.
Urano K; Suzuki S; Machida K; Eguchi N; Sawa N; Kikuchi K; Hattori Y; Usui T
J Toxicol Sci; 2007 Oct; 32(4):367-75. PubMed ID: 17965551
[TBL] [Abstract][Full Text] [Related]
16. Tg.rasH2 Mouse Model for Assessing Carcinogenic Potential of Pharmaceuticals: Industry Survey of Current Practices.
Bogdanffy MS; Lesniak J; Mangipudy R; Sistare FD; Colman K; Garcia-Tapia D; Monticello T; Blanset D
Int J Toxicol; 2020; 39(3):198-206. PubMed ID: 32372678
[TBL] [Abstract][Full Text] [Related]
17. Possible mechanism on enhanced carcinogenesis of genotoxic carcinogens and unsolved mechanisms on lesser carcinogenic susceptibility to some carcinogens in rasH2 mice.
Mitsumori K
J Toxicol Sci; 2003 Dec; 28(5):371-83. PubMed ID: 14746341
[TBL] [Abstract][Full Text] [Related]
18. CB6F1-rasH2 mouse: overview of available data.
Usui T; Mutai M; Hisada S; Takoaka M; Soper KA; McCullough B; Alden C
Toxicol Pathol; 2001; 29 Suppl():90-108. PubMed ID: 11695565
[TBL] [Abstract][Full Text] [Related]
19. The rasH2 mouse model for assessing carcinogenic potential of pharmaceuticals.
Nambiar PR; Morton D
Toxicol Pathol; 2013; 41(8):1058-67. PubMed ID: 23423820
[TBL] [Abstract][Full Text] [Related]
20. Trend analysis of body weight parameters, mortality, and incidence of spontaneous tumors in Tg.rasH2 mice.
Paranjpe MG; Denton MD; Vidmar T; Elbekai RH
Int J Toxicol; 2014; 33(6):475-81. PubMed ID: 25260361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
